UK-based Mundipharma has made steps towards its goals of becoming a leader in the biosimilars field, it has announced this week. It announced on Tuesday that it had secured a distribution licence from South Korea’s Celltrion for Truxima, a biosimilar of Roche's (ROG: SIX) blockbuster drug MabThera (rituximab). This biosimilar received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use last week for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. These are all of the indications of the reference biologic.
If approved, Truxima would be the first rituximab biosimilar approved by the European Commission. Mundipharma and its network of independent associated companies will have exclusive rights to market and distribute Truxima in the UK, Germany, Italy, Ireland, Belgium, Luxembourg and the Netherlands.
It will be the second biosimilar monoclonal antibody to be marketed and distributed by the Mundipharma network.
The company’s managing director Antony Mattessich said: “Mundipharma is establishing itself as a leader in biosimilars with our deep understanding of European markets and track record in delivering marketing excellence in a complex area.
“Biosimilar rituximab has an enormous potential to deliver patient benefits while freeing up resources for novel cancer treatment options. That’s why biosimilars are becoming a key part of our business in Europe and we look forward to building on our partnership with Celltrion and continuing to identify further partnerships in this area.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.